A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of IZD334 in Healthy Adult Participants as Well as an Open-label Cohort to Confirm the Safety, Pharmacokinetics, and Pharmacodynamics in Adult Patients With Cryopyrin-Associated Periodic Syndromes
Latest Information Update: 04 Nov 2021
At a glance
- Drugs IZD 334 (Primary)
- Indications Cryopyrin-associated periodic syndromes
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Inflazome
- 27 Feb 2020 Status changed from recruiting to completed.
- 18 Sep 2019 New trial record
- 13 Sep 2019 Status changed from not yet recruiting to recruiting.